Peter C. Gareiss

An analysis of FDA-approved drugs: natural products and their derivatives

Eric Patridge, Peter C. Gareiss, Michael S. Kinch · Drug Discovery Today · 2015 · 799 citations

Drug Safety, Medicinal Chemistry, Pharmaceutical Research +9

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

Dennis L. Buckley, Inge Van Molle, Peter C. Gareiss et al. · Journal of the American Chemical Society · 2012 · 540 citations · Full text

Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α

Dennis L. Buckley, Jeffrey L. Gustafson, Inge Van Molle et al. · Angewandte Chemie International Edition · 2012 · 280 citations · Full text

Dynamic Combinatorial Selection of Molecules Capable of Inhibiting the (CUG) Repeat RNA−MBNL1 Interaction In Vitro: Discovery of Lead Compounds Targeting Myotonic Dystrophy (DM1)

Peter C. Gareiss, Krzysztof Sobczak, Brian R. McNaughton et al. · Journal of the American Chemical Society · 2008 · 186 citations · Full text

Systems Biology, Engineering, Natural Sciences +14

Identification of Biologically Active, HIV TAR RNA-Binding Small Molecules Using Small Molecule Microarrays

Joanna Sztuba-Solińska, Shilpa R. Shenoy, Peter C. Gareiss et al. · Journal of the American Chemical Society · 2014 · 140 citations · Full text

Drug Target, Biologically Active, Molecular Biology +24